---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-22-000071"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-08-19T23:59:59+00:00"
generated_at: "2026-06-23T22:38:16.295933+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caladrius receives Nasdaq extension to Feb 13, 2023 to regain $1 bid price compliance

## Summary
- Company failed to meet $1 minimum bid price by Aug 17, 2022 initial compliance deadline.
- Nasdaq granted extension to Feb 13, 2023; requires closing bid of $1+ for 10 consecutive days.
- If compliance not demonstrated by Feb 13, 2023, delisting notice will be issued.
- Company may appeal delisting determination, but success cannot be assured.

## SEC filing metadata
- accession: 0000320017-22-000071
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001722000071/0000320017-22-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001722000071/clbs-20220818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-22-000071
- JSON: https://secwatch.observer/filing/0000320017-22-000071.json
- Plain text: https://secwatch.observer/filing/0000320017-22-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.